# US 7,611,719 B2 · Enterovirus, vaccines, medicaments and diagnostic kits > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 7,611,719 B2 - Document ID: US7611719B2 - Status: Granted - Kind: B2 - Application number: 11/285,749 - Filed: 2005-11-21 - Published: 2006-08-17 - Granted: 2009-11-03 - Earliest claimed: 2003-05-21 - Assignees: Amsterdam Institute of Viral Genomics B.V. - Inventors: Henriette Catharina Gerarda Irene Martina Maas; Rui Mang; Petrus Johannes Maria van den Broek; Cornelia Maria van der Hoek - Web page: https://patentgrep.com/patent/US7611719B2 ## CPC - C07K 14/005: from viruses - A61P 9/00: Drugs for disorders of the cardiovascular system - A61P 11/00: Drugs for disorders of the respiratory system - A61P 25/00: Drugs for disorders of the nervous system - A61P 31/12: Antivirals - A61P 31/18: for HIV - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) - C12Q 1/701: {Specific hybridization probes} - A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) - C12N 2770/32321: Viruses as such, e.g. new isolates, mutants or their genomic sequences - C12N 2770/32322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The invention provides a new enteroviral species call EV79, and functional parts, derivatives and analogues of said virus. Proteinaceous molecules capable of specifically binding EV79, such as isolated or recombinant antibodies, are also herewith provided. A virus and/or proteinaceous molecule of the invention is particularly suitable for diagnosis of an EV79-related disease. Vaccines, pharmaceutical compositions and diagnostic kits comprising said virus or proteinaceous molecule are also provided, as well as methods for producing same. A diagnostic kit of the invention may as well comprise a primer/probe capable of amplifying and/or hybridizing the genome or part thereof of EV79. ## Claims ### Claim 1 An isolated and/or recombinant nucleic acid comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:82 and SEQ ID NO:61. ### Claim 2 An isolated and/or recombinant nucleic acid that is at least 95% homologous to a nucleic acid sequence selected from the group consisting of SEQ ID NO: 82 and SEQ ID NO: 61. ### Claim 3 An isolated and/or recombinant nucleic acid comprising a stretch of 100 consecutive nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 82 and SEQ ID NO: 61. ### Claim 4 An isolated and/or recombinant nucleic acid encoding a proteinaceous molecule comprising an amino acid sequence selected from the group consisting of SEQ ID NO:83, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, and SEQ ID NO:63. ### Claim 5 (depends on 1) An isolated or recombinant virus comprising a nucleic acid sequence according to claim 1. ### Claim 6 (depends on 1) A vector comprising a nucleic acid according to claim 1. ### Claim 7 A primer and/or probe comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, and SEQ ID NO:38. ### Claim 8 (depends on 7) A diagnostic kit comprising a primer/probe according to claim 7. ### Claim 9 (depends on 1) An isolated cell comprising a nucleic acid according to claim 1. ### Claim 10 (depends on 9) An isolated cell according to claim 9, wherein said nucleic acid comprises an expressible coding region of SEQ ID NO:82, or a part of said coding region coding for at least a protein comprising a stretch of 30 consecutive amino acids. ### Claim 11 (depends on 9) An isolated cell according to claim 9, wherein said cell is a eukaryotic cell. ### Claim 12 (depends on 1) A gene delivery vehicle comprising a sequence according to claim 1. ### Claim 13 (depends on 5) An attenuated virus according to claim 5. ### Claim 14 A polycistronic messenger RNA comprising an internal ribosomal entry site (IRES) that comprises positions 1 to 748 of SEQ ID NO:82. ### Claim 15 A chimeric enterovirus comprising at least 1000 consecutive nucleotides of SEQ ID NO: 82 and at least 1000 consecutive nucleotides of another enterovirus wherein said latter 1000 consecutive nucleotides comprise a sequence that is more than 5% sequence divergent with SEQ ID NO: 82. ### Claim 16 (depends on 6) An isolated cell comprising a vector according to claim 6.